KMT2A and acute myeloid leukemia: For instance, in mixed-lineage leukemia (MLL) rearranged B-ALL, CAR19 therapy can induce a lineage switch to acute myeloid leukemia (AML), leading to loss of CD19 expression and therapy resistance [17, 18].